These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 34095761)

  • 41. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
    Barbui T; Falanga A
    Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Ferreira Cristina S; Polo B; Lacerda JF
    Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.
    Dos Santos LC; Ribeiro JC; Silva NP; Cerutti J; da Silva MR; Chauffaille Mde L
    Rev Bras Hematol Hemoter; 2011; 33(6):417-24. PubMed ID: 23049357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
    Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Clinical and Hematological Parameters of Janus Kinase 2, Calreticulin or Myeloproliferative Leukemia Virus Oncogene Mutant Essential Thrombocythemia and Triple-Negative Essential Thrombocythemia.
    Yıldız J; Batgi H
    Cureus; 2022 Mar; 14(3):e23171. PubMed ID: 35444868
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Mroczkowska-Bękarciak A; Wróbel T
    Front Genet; 2023; 14():1241912. PubMed ID: 37745842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent insights regarding the molecular basis of myeloproliferative neoplasms.
    Jang MA; Choi CW
    Korean J Intern Med; 2020 Jan; 35(1):1-11. PubMed ID: 31778606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance].
    Tang Q; Zhang XW; Xia L; Jiang NK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):151-156. PubMed ID: 28245393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Mutation Rate and Clinical Characteristics of CALR, JAK2 V617F and MPL W515K Genes in Patients With Primary Thrombocythemia].
    Yu XW; Huang DH; Guo JX; Huang YQ; Xie RT; Cai JF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):866-870. PubMed ID: 29950234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
    Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
    Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
    J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East.
    Safavi M; Monabati A; Safaei A; Mirtalebi MS; Faghih M
    Iran J Pathol; 2021; 16(2):190-194. PubMed ID: 33936230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutational profiling in myelofibrosis: implications for management.
    Bose P; Verstovsek S
    Int J Hematol; 2020 Feb; 111(2):192-199. PubMed ID: 31630335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
    Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
    Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Search for mutations in patients with Philadelphia negative myeloproliferative neoplasms in a public hospital in Chile].
    Jaramillo I; Torres V; Leyton L; Navarrete M; Pilleux L
    Rev Med Chil; 2022 Jul; 150(7):849-854. PubMed ID: 37906817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [CALR gene mutation detection and clinical observation of 150 essential thrombocythemia patients].
    Zhang X; Zhou M; Chao H; Lu X; Cen L
    Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):378-82. PubMed ID: 26031522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
    Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
    Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.